卡介苗对哮喘豚鼠的影响

目的 研究卡介苗对哮喘豚鼠的防治作用。方法 24只豚鼠随机分为阳性对照组、地塞米松组、卡介苗组及阴性对照组,每组6只,除阴性对照组用生理盐水外,其余三组每只腹腔内注射鸡卵蛋白100mg,2周后用1％鸡卵蛋白激发致敏,每次30min,每日1次,持续3d,地塞米松组每次激发前肌注地塞米松2mg/kg,卡介苗组每次激发前肌往卡介苗30mg/kg,阳性对照组每次激发前30min肌注生理盐水2ml,最后用乌拉坦麻醉,检验动脉血气分析参数,嗜酸粒细胞(EOS)计数等参数,所有参数用t检验或卡方检验分析。结果 阳性对照组与其它三组比较,在豚鼠的发病程度、动脉血气分析、外周血EOS计数、支气管肺泡灌洗液中EOS计数、支气管病理切片每20个高倍视野EOS计数均有明显差异(P<0.05或P<0.01)。结论 卡介苗能够抑制动物模型中的哮喘反应。     

肺癌患者血清肿瘤特异生长因子检测及临床意义

目的 :研究TSGF在肺癌诊断、疗效判定中的临床应用价值。方法 :利用生化比色法测定了 18例肺良性病变患者 ,2 4例肺癌患者及 9例肺癌患者治疗后血清中TSGF水平。结果 :肺癌患者未经治疗前其血清TS GF水平及阳性率明显高于肺良性病变患者 ,其敏感性为 75 .0 % ,特异性为 77.8%。经有效化学治疗后肺癌患者血清TSGF明显下降。结论 :血清TSGF检测对肺癌的诊断、疗效观察有较重要的意义。     

热缺血供体同种异体犬肺移植术后早期肺功能的观察

目的　观察犬热缺血供体同种异体肺移植术后早期移植肺功能情况。方法　采用室温下热缺血 3 0min、LPD液灌注后 4℃保存 2 5h时的供肺 ,行右肺同种异体移植手术 7例 ,术前及监测恢复灌注 0 5 ,1,2及 4h的动脉血氧分压 (PaO2 )、肺动态顺应性 (Cdyn)、平均肺动脉压 (mPAP)、肺毛细血管楔压 (PCWP)和心输出量的变化 (CO)。结果　所有受体犬在观察期间均存活。恢复灌注 4h内的肺功能各指标变化差异无显著性 (P >0 0 5 ) ,或者虽然有统计学差异 ,但仍有较好的绝对水平。结论　热缺血 3 0min低温保存 2 5h的供肺可以维持生命 ,恢复灌注后 ,受缺血再灌注损伤的影响 ,在灌注后一段时间内 ,供肺功能下降 ,但仍可较好支持生命。     

Airway challenge test with propranolol

We investigated airway response to propranolol in 48 asthmatics, 17 subjects with chronic bronchitis and 19 normal subjects. The positive rate for propranolol challenge was 93.8% in asthma group, 5.9% in chronic bronchitis group while none in normal group had positive response. The challenge was highly reproducible, and it had few side-effects. This indicated that the challenge was specific and sensitive in diagnosis of asthma, it was a safe, reliable method of measuring non-specific airway responsiveness. Furthermore we also demonstrated that PC20 for propranolol did not relate to PC20 for methacholine, and that the calibre of airway did not significantly influence the airway response to propranolol.     

Effect of gravitation for detection of bronchioloalveolar carcinoma on computed tomography

A 64-year-old female was found to have localized ground-glass opacity (GGO) in the middle lobe on a chest computed tomography (CT) for screening. Middle lobectomy with video-assisted thoracoscopic surgery (VATS) was undertaken, and pathological diagnosis was a bronchioloalveolar carcinoma (BAC) in stage IA. A follow-up CT a year following the surgery revealed localized GGO in area S⁶ of the left lung. However, it disappeared during the gravitation-dependent gradient in the observation period. The patient was scanned again under prone position to exclude the gravitational effect, resulting in definite detection of the GGO. Left extended S⁶ segmentectomy with VATS was performed, and pathological diagnosis was a BAC in stage IA. As GGO existing in a gravitation-dependent area may be masked by the gravitation-dependent density, a change of the scanning position may lead to a proper detection of the tumor for the diagnosis of BAC.     

Influence of impaired T- and B-cell compartments on efficacy of IVIg in dysimmune neuropathies

Autoimmune mechanisms are postulated to play a role in the development and progression of dysimmune neuropathies (DN). We investigated the relation between lymphocyte number and marker expression, and disease activity in 20 patients with DN under intravenous immunoglobulins (IVIg) treatment. B- and T-lymphocyte markers were studied by flow cytometry of the expression of CD5, CD25, CD23 and CD38 markers on B cells and of CD3, CD4 and CD8 markers, respectively. These parameters were compared with those obtained from matched healthy volunteers. The proportions of CD38+ B cells were higher in patients compared with those of controls. Proportions of activated CD4+ and CD8+ T cells were comparable in peripheral blood mononuclear cells of patients and controls, but a significant reduction of the absolute numbers of CD3+, CD4+ and CD8+ cells were observed in DN patients. The percentages of CD25+ memory T cells were instead significantly increased in DN patients. Lastly, T-cell reduction and the CD19/CD38 ratio over total B (CD19+) cells directly correlated with a poor response to IVIg therapy. In DN, whereas T-cell number is reduced, activated T and B cells are increased, thus suggesting an intrinsic defect of the immune response.